207 related articles for article (PubMed ID: 11212276)
1. Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412.
Zaugg K; Rocha S; Resch H; Hegyi I; Oehler C; Glanzmann C; Fabbro D; Bodis S; Pruschy M
Cancer Res; 2001 Jan; 61(2):732-8. PubMed ID: 11212276
[TBL] [Abstract][Full Text] [Related]
2. PKC412--a protein kinase inhibitor with a broad therapeutic potential.
Fabbro D; Ruetz S; Bodis S; Pruschy M; Csermak K; Man A; Campochiaro P; Wood J; O'Reilly T; Meyer T
Anticancer Drug Des; 2000 Feb; 15(1):17-28. PubMed ID: 10888033
[TBL] [Abstract][Full Text] [Related]
3. The phosphatidylinositide 3'-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C.
Tenzer A; Zingg D; Rocha S; Hemmings B; Fabbro D; Glanzmann C; Schubiger PA; Bodis S; Pruschy M
Cancer Res; 2001 Nov; 61(22):8203-10. PubMed ID: 11719451
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase C inhibitor and irradiation-induced apoptosis: relevance of the cytochrome c-mediated caspase-9 death pathway.
Rocha S; Soengas MS; Lowe SW; Glanzmann C; Fabbro D; Winterhalter K; Bodis S; Pruschy M
Cell Growth Differ; 2000 Sep; 11(9):491-9. PubMed ID: 11007454
[TBL] [Abstract][Full Text] [Related]
5. Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro.
Ganeshaguru K; Wickremasinghe RG; Jones DT; Gordon M; Hart SM; Virchis AE; Prentice HG; Hoffbrand AV; Man A; Champain K; Csermak K; Mehta AB
Haematologica; 2002 Feb; 87(2):167-76. PubMed ID: 11836167
[TBL] [Abstract][Full Text] [Related]
6. Antitumor and normal cell protective effect of PKC412 in the athymic mouse model of ovarian cancer.
Kim M; Park IY; Lim J; Kim Y; Han KT; Chung WH; Han K
Ann Clin Lab Sci; 2006; 36(4):455-60. PubMed ID: 17127735
[TBL] [Abstract][Full Text] [Related]
7. Effect of PKC412, an inhibitor of protein kinase C, on spontaneous metastatic model mice.
Nakamura K; Yoshikawa N; Yamaguchi Y; Kagota S; Shinozuka K; Kunitomo M
Anticancer Res; 2003; 23(2B):1395-9. PubMed ID: 12820400
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo.
Maggiorella L; Deutsch E; Frascogna V; Chavaudra N; Jeanson L; Milliat F; Eschwege F; Bourhis J
Cancer Res; 2003 May; 63(10):2513-7. PubMed ID: 12750274
[TBL] [Abstract][Full Text] [Related]
9. Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo.
Hofstetter B; Vuong V; Broggini-Tenzer A; Bodis S; Ciernik IF; Fabbro D; Wartmann M; Folkers G; Pruschy M
Clin Cancer Res; 2005 Feb; 11(4):1588-96. PubMed ID: 15746064
[TBL] [Abstract][Full Text] [Related]
10. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.
Hess C; Vuong V; Hegyi I; Riesterer O; Wood J; Fabbro D; Glanzmann C; Bodis S; Pruschy M
Br J Cancer; 2001 Dec; 85(12):2010-6. PubMed ID: 11747347
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
Bianco C; Tortora G; Bianco R; Caputo R; Veneziani BM; Caputo R; Damiano V; Troiani T; Fontanini G; Raben D; Pepe S; Bianco AR; Ciardiello F
Clin Cancer Res; 2002 Oct; 8(10):3250-8. PubMed ID: 12374696
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of the new selective protein kinase C inhibitor 4'-N-benzoyl staurosporine on murine and human tumor models.
Ikegami Y; Yano S; Nakao K; Fujita F; Fujita M; Sakamoto Y; Murata N; Isowa K
Arzneimittelforschung; 1995 Nov; 45(11):1225-30. PubMed ID: 8929245
[TBL] [Abstract][Full Text] [Related]
13. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2.
Pyo H; Choy H; Amorino GP; Kim JS; Cao Q; Hercules SK; DuBois RN
Clin Cancer Res; 2001 Oct; 7(10):2998-3005. PubMed ID: 11595687
[TBL] [Abstract][Full Text] [Related]
14. Individual dose and scheduling determine the efficacy of combining cytotoxic anticancer agents with a kinase inhibitor in non-small-cell lung cancer.
Meiler J; Guyot M; Hoffarth S; Wesarg E; Höhn Y; Breitenbuecher F; Schuler M
J Cancer Res Clin Oncol; 2012 Aug; 138(8):1385-94. PubMed ID: 22488173
[TBL] [Abstract][Full Text] [Related]
15. PKC 412 small-molecule tyrosine kinase inhibitor: single-compound therapy for pancreatic cancer.
El Fitori J; Su Y; Büchler P; Ludwig R; Giese NA; Büchler MW; Quentmeier H; Hines OJ; Herr I; Friess H
Cancer; 2007 Oct; 110(7):1457-68. PubMed ID: 17676584
[TBL] [Abstract][Full Text] [Related]
16. Acriflavine enhances radiosensitivity of colon cancer cells through endoplasmic reticulum stress-mediated apoptosis.
Lim MJ; Ahn JY; Han Y; Yu CH; Kim MH; Lee SL; Lim DS; Song JY
Int J Biochem Cell Biol; 2012 Aug; 44(8):1214-22. PubMed ID: 22564437
[TBL] [Abstract][Full Text] [Related]
17. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation.
Spitz FR; Nguyen D; Skibber JM; Meyn RE; Cristiano RJ; Roth JA
Clin Cancer Res; 1996 Oct; 2(10):1665-71. PubMed ID: 9816114
[TBL] [Abstract][Full Text] [Related]
18. PKC412 induces apoptosis through a caspase-dependent mechanism in human keloid-derived fibroblasts.
Nakazono-Kusaba A; Takahashi-Yanaga F; Miwa Y; Morimoto S; Furue M; Sasaguri T
Eur J Pharmacol; 2004 Aug; 497(2):155-60. PubMed ID: 15306200
[TBL] [Abstract][Full Text] [Related]
19. Treatment of human glioblastoma cells with the staurosporine derivative CGP 41251 inhibits CDC2 and CDK2 kinase activity and increases radiation sensitivity.
Begemann M; Kashimawo SA; Heitjan DF; Schiff PB; Bruce JN; Weinstein IB
Anticancer Res; 1998; 18(4A):2275-82. PubMed ID: 9703866
[TBL] [Abstract][Full Text] [Related]
20. Comparison of effects of doxorubicin and radiation on p53-dependent apoptosis in vivo.
Hayakawa K; Hasegawa M; Kawashima M; Nakamura Y; Matsuura M; Toda H; Hayakawa K; Mitsuhashi N; Niibe H
Oncol Rep; 2000; 7(2):267-70. PubMed ID: 10671669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
